Meitheal Pharmaceuticals has Bendamustine Hydrochloride for Injection, USP Now Available

Share Facebook icon Twitter icon Linkedin icon

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Bendamustine Hydrochloride for Injection, USP, in 25 mg per vial in a single-dose vial and 100 mg per vial in a single-dose vial.

Meitheal will offer Bendamustine Hydrochloride for Injection, USP in a pack of 1 vial for both presentations.


Bendamustine Hydrochloride for Injection is an alkylating drug indicated for treatment of patients with:

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
  • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
  • For full prescribing information, and safety information, please click on the following link.


Learn more about Bendamustine Hydrochloride for Injection

This Website Uses Cookies

This website uses cookies to help give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and help us make improvements to our site. You can read more about our use of cookies in our Privacy Policy.

Manage Consent Preferences

Always Active

Necessary cookies enable core functionality such as security and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

These cookies are set to provide quantitative measures of website visitors. Information collected with these cookies is used in operations to measure website performance. With the usage of these cookies we are able to count visits and traffic sources to improve our site. The data is collected in a way that does not directly identify anyone.
Accept all cookies Confirm my choices